{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T19:45:50Z","timestamp":1795117550348,"version":"4.10.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:00:00Z","timestamp":1616803200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:00:00Z","timestamp":1616803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bayer Pharma AG or Piramal Imaging"},{"name":"Fundaci\u00f3 ACE Institut Catal\u00e0 de Neuroci\u00e8ncies Aplicades, Grifols, Life Molecular Imaging, Araclon Biotech, Alkahest, Laboratorio de an\u00e1lisis Echevarne and IrsiCaixa"},{"name":"EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking","award":["115952"],"award-info":[{"award-number":["115952"]}]},{"DOI":"10.13039\/100007333","name":"Alzheimer's Disease Neuroimaging Initiative","doi-asserted-by":"publisher","award":["National Institutes of Health Grant U01 AG024904"],"award-info":[{"award-number":["National Institutes of Health Grant U01 AG024904"]}],"id":[{"id":"10.13039\/100007333","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007333","name":"Alzheimer's Disease Neuroimaging Initiative","doi-asserted-by":"publisher","award":["Department of Defense award number W81XWH-12-2-0012"],"award-info":[{"award-number":["Department of Defense award number W81XWH-12-2-0012"]}],"id":[{"id":"10.13039\/100007333","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>A low amount and extent of A\u03b2 deposition at early stages of Alzheimer\u2019s disease (AD) may limit the use of previously developed pathology-proven composite SUVR cutoffs. This study aims to characterize the population with earliest abnormal A\u03b2 accumulation using <jats:sup>18<\/jats:sup>F-florbetaben PET. Quantitative thresholds for the early (SUVR<jats:sub>early<\/jats:sub>) and established (SUVR<jats:sub>estab<\/jats:sub>) A\u03b2 deposition were developed, and the topography of early A\u03b2 deposition was assessed. Subsequently, A\u03b2 accumulation over time, progression from mild cognitive impairment (MCI) to AD dementia, and tau deposition were assessed in subjects with early and established A\u03b2 deposition.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study population consisted of 686 subjects (<jats:italic>n<\/jats:italic>\u2009=\u2009287 (cognitively normal healthy controls), <jats:italic>n<\/jats:italic>\u2009=\u2009166 (subjects with subjective cognitive decline (SCD)), <jats:italic>n<\/jats:italic>\u2009=\u2009129 (subjects with MCI), and <jats:italic>n<\/jats:italic>\u2009=\u2009101 (subjects with AD dementia)). Three categories in the A\u03b2-deposition continuum were defined based on the developed SUVR cutoffs: A\u03b2-negative subjects, subjects with early A\u03b2 deposition (\u201cgray zone\u201d), and subjects with established A\u03b2 pathology.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>SUVR using the whole cerebellum as the reference region and centiloid (CL) cutoffs for early and established amyloid pathology were 1.10 (13.5 CL) and 1.24 (35.7 CL), respectively. Cingulate cortices and precuneus, frontal, and inferior lateral temporal cortices were the regions showing the initial pathological tracer retention. Subjects in the \u201cgray zone\u201d or with established A\u03b2 pathology accumulated more amyloid over time than A\u03b2-negative subjects. After a 4-year clinical follow-up, none of the A\u03b2-negative or the gray zone subjects progressed to AD dementia while 91% of the MCI subjects with established A\u03b2 pathology progressed. Tau deposition was infrequent in those subjects without established A\u03b2 pathology.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study supports the utility of using two cutoffs for amyloid PET abnormality defining a \u201cgray zone\u201d: a lower cutoff of 13.5 CL indicating emerging A\u03b2 pathology and a higher cutoff of 35.7 CL where amyloid burden levels correspond to established neuropathology findings. These cutoffs define a subset of subjects characterized by pre-AD dementia levels of amyloid burden that precede other biomarkers such as tau deposition or clinical symptoms and accelerated amyloid accumulation. The determination of different amyloid loads, particularly low amyloid levels, is useful in determining who will eventually progress to dementia. Quantitation of amyloid provides a sensitive measure in these low-load cases and may help to identify a group of subjects most likely to benefit from intervention.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Data used in this manuscript belong to clinical trials registered in ClinicalTrials.gov (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00928304\">NCT00928304<\/jats:ext-link>, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00750282\">NCT00750282<\/jats:ext-link>, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01138111\">NCT01138111<\/jats:ext-link>, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02854033\">NCT02854033<\/jats:ext-link>) and EudraCT (2014-000798-38).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-021-00807-6","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T13:02:21Z","timestamp":1616850141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Early detection of amyloid load using 18F-florbetaben PET"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5669-269X","authenticated-orcid":false,"given":"Santiago","family":"Bullich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Ro\u00e9-Vellv\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Marqui\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henryk","family":"Barthel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor L.","family":"Villemagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Sanabria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Tartari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Sotolongo-Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Dor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Koglin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Perrotin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandar","family":"Jovalekic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"De Santi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llu\u00eds","family":"T\u00e1rraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Sabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Seibyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Boada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,27]]},"reference":[{"issue":"4","key":"807_CR1","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0197-4580(97)00056-0","volume":"18","author":"H Braak","year":"1997","unstructured":"Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351\u20137.","journal-title":"Neurobiol Aging"},{"issue":"4","key":"807_CR2","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357\u201367.","journal-title":"Lancet Neurol"},{"issue":"8","key":"807_CR3","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1001\/archneurol.2012.90","volume":"69","author":"K Blennow","year":"2012","unstructured":"Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol. 2012;69(8):1002\u201310.","journal-title":"Arch Neurol"},{"issue":"1","key":"807_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/WNF.0b013e31823a13d3","volume":"35","author":"K Uenaka","year":"2012","unstructured":"Uenaka K, Nakano M, Willis BA, Friedrich S, Ferguson-Sells L, Dean RA, et al. Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid beta monoclonal antibody solanezumab in Japanese and white patients with mild to moderate Alzheimer disease. Clin Neuropharmacol. 2012;35(1):25\u20139.","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"807_CR5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jalz.2016.04.001","volume":"12","author":"S Weninger","year":"2016","unstructured":"Weninger S, Carrillo MC, Dunn B, Aisen PS, Bateman RJ, Kotz JD, et al. Collaboration for Alzheimer\u2019s prevention: principles to guide data and sample sharing in preclinical Alzheimer\u2019s disease trials. Alzheimers Dement. 2016;12(5):631\u20132.","journal-title":"Alzheimers Dement"},{"issue":"7662","key":"807_CR6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/547153a","volume":"547","author":"E McDade","year":"2017","unstructured":"McDade E, Bateman RJ. Stop Alzheimer\u2019s before it starts. Nature. 2017;547(7662):153\u20135.","journal-title":"Nature."},{"issue":"2","key":"807_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S2215-0366(15)00454-X","volume":"3","author":"CW Ritchie","year":"2016","unstructured":"Ritchie CW, Molinuevo JL, Truyen L, Satlin A, Van der Geyten S, Lovestone S. Development of interventions for the secondary prevention of Alzheimer\u2019s dementia: the European Prevention of Alzheimer\u2019s Dementia (EPAD) project. Lancet Psychiatry. 2016;3(2):179\u201386.","journal-title":"Lancet Psychiatry"},{"issue":"111","key":"807_CR8","doi-asserted-by":"publisher","first-page":"111cm33","DOI":"10.1126\/scitranslmed.3002609","volume":"3","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Jack CR Jr, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3(111):111cm33.","journal-title":"Sci Transl Med"},{"issue":"8","key":"807_CR9","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","volume":"11","author":"O Sabri","year":"2015","unstructured":"Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: phase 3 study. Alzheimers Dement. 2015;11(8):964\u201374.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"807_CR10","doi-asserted-by":"publisher","first-page":"900","DOI":"10.2967\/jnumed.115.161927","volume":"57","author":"J Seibyl","year":"2016","unstructured":"Seibyl J, Catafau AM, Barthel H, Ishii K, Rowe CC, Leverenz JB, et al. Impact of training method on the robustness of the visual assessment of 18F-florbetaben PET scans: results from a phase-3 study. J Nucl Med. 2016;57(6):900\u20136.","journal-title":"J Nucl Med"},{"issue":"8","key":"807_CR11","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.2967\/jnumed.116.187351","volume":"58","author":"S Bullich","year":"2017","unstructured":"Bullich S, Villemagne VL, Catafau AM, Jovalekic A, Koglin N, Rowe CC, et al. Optimal reference region to measure longitudinal amyloid-beta change with 18F-florbetaben PET. J Nucl Med. 2017;58(8):1300\u20136.","journal-title":"J Nucl Med"},{"key":"807_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.nicl.2017.04.025","volume":"15","author":"S Bullich","year":"2017","unstructured":"Bullich S, Seibyl J, Catafau AM, Jovalekic A, Koglin N, Barthel H, et al. Optimized classification of 18F-florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment. Neuroimage Clin. 2017;15:325\u201332.","journal-title":"Neuroimage Clin"},{"issue":"5","key":"807_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","volume":"10","author":"H Barthel","year":"2011","unstructured":"Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer\u2019s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10(5):424\u201335.","journal-title":"Lancet Neurol"},{"issue":"5","key":"807_CR14","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1212\/WNL.0000000000001212","volume":"84","author":"D Jennings","year":"2015","unstructured":"Jennings D, Seibyl J, Sabbagh M, Lai F, Hopkins W, Bullich S, et al. Age dependence of brain beta-amyloid deposition in Down syndrome: an [18F] florbetaben PET study. Neurology. 2015;84(5):500\u20137.","journal-title":"Neurology."},{"issue":"6","key":"807_CR15","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s00259-015-3300-6","volume":"43","author":"T Tuszynski","year":"2016","unstructured":"Tuszynski T, Rullmann M, Luthardt J, Butzke D, Tiepolt S, Gertz HJ, et al. Evaluation of software tools for automated identification of neuroanatomical structures in quantitative beta-amyloid PET imaging to diagnose Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2016;43(6):1077\u201387.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"807_CR16","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.2967\/jnumed.111.089730","volume":"52","author":"VL Villemagne","year":"2011","unstructured":"Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52(8):1210\u20137.","journal-title":"J Nucl Med"},{"issue":"6","key":"807_CR17","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jalz.2019.02.005","volume":"15","author":"V Dor\u00e9","year":"2019","unstructured":"Dor\u00e9 V, Bullich S, Rowe CC, Bourgeat P, Konate S, Sabri O, et al. Comparison of 18F-florbetaben quantification results using the standard centiloid, MR-based, and MR-less CapAIBL((R)) approaches: validation against histopathology. Alzheimers Dement. 2019;15(6):807\u201316.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"807_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/alzrt158","volume":"5","author":"K Ong","year":"2013","unstructured":"Ong K, Villemagne VL, Bahar-Fuchs A, Lamb F, Ch\u00e9telat G, Raniga P, et al. (18)F-florbetaben Abeta imaging in mild cognitive impairment. Alzheimers Res Ther. 2013;5(1):4.","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"807_CR19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1212\/WNL.0000000000007747","volume":"93","author":"GN Bischof","year":"2019","unstructured":"Bischof GN, Jacobs HIL. Subthreshold amyloid and its biological and clinical meaning: long way ahead. Neurology. 2019;93(2):72\u20139.","journal-title":"Neurology."},{"issue":"2","key":"807_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.2967\/jnumed.119.235879","volume":"61","author":"E Fantoni","year":"2020","unstructured":"Fantoni E, Collij L, Lopes Alves I, Buckley C, Farrar G. AMYPAD consortium. The spatial-temporal ordering of amyloid pathology and opportunities for PET imaging. J Nucl Med. 2020;61(2):166\u201371.","journal-title":"J Nucl Med"},{"issue":"20","key":"807_CR21","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1212\/WNL.0000000000004643","volume":"89","author":"MJ Grothe","year":"2017","unstructured":"Grothe MJ, Barthel H, Sepulcre J, Dyrba M, Sabri O, Teipel SJ. In vivo staging of regional amyloid deposition. Neurology. 2017;89(20):2031\u20138.","journal-title":"Neurology."},{"key":"807_CR22","doi-asserted-by":"crossref","unstructured":"Mattsson N, Palmqvist S, Stomrud E, Vogel J, Hansson O. Staging beta-amyloid pathology with amyloid positron emission tomography. JAMA Neurol. 2019;76(11):1319\u201329.","DOI":"10.1001\/jamaneurol.2019.2214"},{"issue":"11","key":"807_CR23","doi-asserted-by":"publisher","first-page":"e1538","DOI":"10.1212\/WNL.0000000000010256","volume":"95","author":"LE Collij","year":"2020","unstructured":"Collij LE, Heeman F, Salvad\u00f3 G, Ingala S, Altomare D, de Wilde A, et al. Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology. 2020;95(11):e1538\u201353.","journal-title":"Neurology."},{"issue":"1","key":"807_CR24","first-page":"e12037","volume":"12","author":"TA Pascoal","year":"2020","unstructured":"Pascoal TA, Therriault J, Mathotaarachchi S, Kang MS, Shin M, Benedet AL, et al. Topographical distribution of Abeta predicts progression to dementia in Abeta positive mild cognitive impairment. Alzheimers Dement (Amst). 2020;12(1):e12037.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"10","key":"807_CR25","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.jalz.2018.04.011","volume":"14","author":"BJ Hanseeuw","year":"2018","unstructured":"Hanseeuw BJ, Betensky RA, Mormino EC, Schultz AP, Sepulcre J, Becker JA, et al. PET staging of amyloidosis using striatum. Alzheimers Dement. 2018;14(10):1281\u201392.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"807_CR26","first-page":"100","volume":"4","author":"O Rodriguez-Gomez","year":"2017","unstructured":"Rodriguez-Gomez O, Sanabria A, Perez-Cordon A, Sanchez-Ruiz D, Abdelnour C, Valero S, et al. FACEHBI: a prospective study of risk factors, biomarkers and cognition in a cohort of individuals with subjective cognitive decline. Study rationale and research protocols. J Prev Alzheimers Dis. 2017;4(2):100\u20138.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"807_CR27","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.neuroimage.2009.01.057","volume":"46","author":"A Joshi","year":"2009","unstructured":"Joshi A, Koeppe RA, Fessler JA. Reducing between scanner differences in multi-center PET studies. Neuroimage. 2009;46(1):154\u20139.","journal-title":"Neuroimage."},{"issue":"1","key":"807_CR28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1006\/nimg.2001.0978","volume":"15","author":"N Tzourio-Mazoyer","year":"2002","unstructured":"Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15(1):273\u201389.","journal-title":"Neuroimage."},{"issue":"2","key":"807_CR29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","volume":"7","author":"CC Rowe","year":"2008","unstructured":"Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, et al. Imaging of amyloid beta in Alzheimer\u2019s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7(2):129\u201335.","journal-title":"Lancet Neurol"},{"issue":"1","key":"807_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1\u201315 e1\u20134.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"807_CR31","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s00259-017-3749-6","volume":"44","author":"CC Rowe","year":"2017","unstructured":"Rowe CC, Dor\u00e9 V, Jones G, Baxendale D, Mulligan RS, Bullich S, et al. 18F-Florbetaben PET beta-amyloid binding expressed in centiloids. Eur J Nucl Med Mol Imaging. 2017;44(12):2053\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"807_CR32","doi-asserted-by":"publisher","first-page":"822","DOI":"10.2967\/jnumed.117.194720","volume":"59","author":"A Whittington","year":"2018","unstructured":"Whittington A, Sharp DJ, Gunn RN. Spatiotemporal distribution of \u03b2-amyloid in Alzheimer disease is the result of heterogeneous regional carrying capacities. J Nucl Med. 2018;59(5):822\u20137.","journal-title":"J Nucl Med"},{"key":"807_CR33","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1212\/WNL.41.4.479","volume":"41","author":"SS Mirra","year":"1991","unstructured":"Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer\u2019s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer\u2019s disease. Neurology. 1991;41:479\u201386.","journal-title":"Neurology."},{"key":"807_CR34","doi-asserted-by":"crossref","unstructured":"Bullich S. Converging evidence for a \u201cgray-zone\u201d of amyloid burden and its relevance. in AAIC. 2020. Virtual.","DOI":"10.1002\/alz.044786"},{"issue":"1","key":"807_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13195-019-0478-z","volume":"11","author":"G Salvad\u00f3","year":"2019","unstructured":"Salvad\u00f3 G, Molinuevo JL, Brugulat-Serrat A, Falcon C, Grau-Rivera O, Su\u00e1rez-Calvet M, et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimers Res Ther. 2019;11(1):27.","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"807_CR36","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.neuroimage.2011.07.098","volume":"59","author":"EC Mormino","year":"2012","unstructured":"Mormino EC, Brandel MG, Madison CM, Rabinovici GD, Marks S, Baker SL, et al. Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage. 2012;59(2):1152\u201360.","journal-title":"Neuroimage."},{"issue":"2","key":"807_CR37","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","volume":"15","author":"R La Joie","year":"2019","unstructured":"La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, et al. Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer\u2019s disease neuropathology. Alzheimers Dement. 2019;15(2):205\u201316.","journal-title":"Alzheimers Dement"},{"issue":"Pt 7","key":"807_CR38","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1093\/brain\/awv112","volume":"138","author":"S Villeneuve","year":"2015","unstructured":"Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, Madison C, Ayakta N, Ghosh PM, et al. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain. 2015;138(Pt 7):2020\u201333.","journal-title":"Brain."},{"issue":"2","key":"807_CR39","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/ana.24711","volume":"80","author":"H Cho","year":"2016","unstructured":"Cho H, Choi JY, Hwang MS, Kim YJ, Lee HM, Lee HS, et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016;80(2):247\u201358.","journal-title":"Ann Neurol"},{"issue":"1","key":"807_CR40","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41467-017-01150-x","volume":"8","author":"S Palmqvist","year":"2017","unstructured":"Palmqvist S, Sch\u00f6ll M, Strandberg O, Mattsson N, Stomrud E, Zetterberg H, et al. Earliest accumulation of \u03b2-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun. 2017;8(1):1214.","journal-title":"Nat Commun"},{"issue":"14","key":"807_CR41","doi-asserted-by":"publisher","first-page":"e1512","DOI":"10.1212\/WNL.0000000000009216","volume":"94","author":"T Guo","year":"2020","unstructured":"Guo T, Landau SM, Jagust WJ. Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults. Neurology. 2020;94(14):e1512\u201324.","journal-title":"Neurology."},{"issue":"11","key":"807_CR42","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.jalz.2018.05.013","volume":"14","author":"T Guo","year":"2018","unstructured":"Guo T, Dukart J, Brendel M, Rominger A, Grimmer T, Yakushev I. Rate of beta-amyloid accumulation varies with baseline amyloid burden: implications for anti-amyloid drug trials. Alzheimers Dement. 2018;14(11):1387\u201396.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"807_CR43","doi-asserted-by":"publisher","first-page":"fcaa007","DOI":"10.1093\/braincomms\/fcaa007","volume":"2","author":"PS Insel","year":"2020","unstructured":"Insel PS, Mormino EC, Aisen PS, Thompson WK, Donohue MC. Neuroanatomical spread of amyloid beta and tau in Alzheimer\u2019s disease: implications for primary prevention. Brain Commun. 2020;2(1):fcaa007.","journal-title":"Brain Commun"},{"issue":"5","key":"807_CR44","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/alz.12069","volume":"16","author":"I Lopes Alves","year":"2020","unstructured":"Lopes Alves I, Collij LE, Altomare D, Frisoni GB, Saint-Aubert L, Payoux P, et al. Quantitative amyloid PET in Alzheimer\u2019s disease: the AMYPAD prognostic and natural history study. Alzheimers Dement. 2020;16(5):750\u20138.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"807_CR45","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.2967\/jnumed.117.200964","volume":"59","author":"S Bullich","year":"2018","unstructured":"Bullich S, Barthel H, Koglin N, Becker GA, De Santi S, Jovalekic A, et al. Validation of noninvasive tracer kinetic analysis of (18)F-Florbetaben PET using a dual-time-window acquisition protocol. J Nucl Med. 2018;59(7):1104\u201310.","journal-title":"J Nucl Med"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00807-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-021-00807-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00807-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T13:02:46Z","timestamp":1616850166000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-021-00807-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,27]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["807"],"URL":"https:\/\/doi.org\/10.1186\/s13195-021-00807-6","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,27]]},"assertion":[{"value":"23 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All studies were conducted in accordance with the Declaration of Helsinki and after approval of the local ethics committees of the participating centers. All participants (or their legal representatives) provided written informed consent prior to recruitment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SB, NRV, NK, AM, AP, AJ, and AS are employees of Life Molecular Imaging GmbH (formerly Piramal Imaging GmbH). SDS is an employee of Eisai Inc. and a former employee of Life Molecular Imaging Inc. (formerly Piramal Pharma Inc). HB and OS received research support, consultant honoraria, and travel expenses from Piramal Imaging GmbH. Victor L. Villemagne has received speaker\u2019s honoraria from Piramal Imaging, GE Healthcare, Avid Pharmaceuticals, AstraZeneca, and Hoffmann-La Roche and consulting fees for Novartis, Lundbeck, Abbvie, Shanghai Green Valley Pharmaceutical Co. LTD, and Hoffmann-La Roche. Christopher C. Rowe has received research grants from Bayer Schering Pharma, Piramal Imaging, Avid Radiopharmaceuticals, Navidea, GE Healthcare, AstraZeneca, and Biogen. John Seibyl holds equity in Invicro and consulting fees from LMI, Roche, Biogen, AbVie, and Invicro. M. Boada has received research funds from the following private donors: Grifols SA, Caixabank S.A., Piramal Imaging, Araclon Biotech, Laboratorios Echevarne, Fundaci\u00f3 Castell de Peralada, and Fundaci\u00f3 La Pedrera and has participated in advisory boards of Araclon Biotech, Biogen, Bioib\u00e9rica, Eisai, Grifols, Lilly, Merck, Nutricia, Roche, Schwabe Farma, Servier, and Kyowa Kirin.No other potential conflict of interest relevant to this article was reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}